EU - From Lab to Market - Successful Technology Transfer Journeys - Case: Atlantic Therapeutics

Eventos de Innovación
29/06/2022
EU - From Lab to Market - Successful Technology Transfer Journeys - Case: Atlantic Therapeutics
Eventos de Innovación
Unidad de comunicación
T +34 848 422 201
29/06/2022
Añadir al calendario 2022-06-29 10:30:00 2022-06-17 14:33:00 EU - From Lab to Market - Successful Technology Transfer Journeys - Case: Atlantic Therapeutics A case of successful technology transfer ventures: Research collaboration between University College Dublin (UCD) and Bio‑Medical Research (BMR) led to the development of a novel training device for the treatment of stress-induced urinary incontinence.   UCD licensed the technology to BMR, which validated the device in clinical trials, secured regulatory approval and launched it in Europe. BMR established Atlantic Therapeutics as a spin-out company to secure investment to target the US market. Atlantic Therapeutics, its flagship product, offers patients safe, non-invasive and cost-effective treatment for stress-induced urinary incontinence, improving the quality of lives.   Improving quality of life. - In academy-industry collaborations, recognise all partners' needs and define incentives and criteria so that the company can act as the commercial partner. - A joint ownership management agreement is necessary to facilitate later commercialisation if joint foreground IP is anticipated. - The deal structure should always be benchmarked so that it is fair and reasonable and reflects industry norms. - Agree on key development and commercial milestones early, to guide and facilitate market success, but be willing to amend as necessary.   More information Register here Online webinar https://ec.europa.eu/info/departments/small-and-medium-sized-enterprises_en https://www.epo.org/about-us/services-and-activities/academy.html https://ec.europa.eu/info/departments/small-and-medium-sized-enterprises_en https://www.epo.org/about-us/services-and-activities/academy.html Europe/Madrid public

A case of successful technology transfer ventures:

Research collaboration between University College Dublin (UCD) and Bio‑Medical Research (BMR) led to the development of a novel training device for the treatment of stress-induced urinary incontinence.

 

UCD licensed the technology to BMR, which validated the device in clinical trials, secured regulatory approval and launched it in Europe.

BMR established Atlantic Therapeutics as a spin-out company to secure investment to target the US market.

Atlantic Therapeutics, its flagship product, offers patients safe, non-invasive and cost-effective treatment for stress-induced urinary incontinence, improving the quality of lives.

 

Improving quality of life.

- In academy-industry collaborations, recognise all partners' needs and define incentives and criteria so that the company can act as the commercial partner.

- A joint ownership management agreement is necessary to facilitate later commercialisation if joint foreground IP is anticipated.

- The deal structure should always be benchmarked so that it is fair and reasonable and reflects industry norms.

- Agree on key development and commercial milestones early, to guide and facilitate market success, but be willing to amend as necessary.

 

More information

Register here